90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. purchased a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 90,563 shares of the company's stock, valued at approximately $2,414,000. D. E. Shaw & Co. Inc. owned 0.32% of Castle Biosciences as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Covestor Ltd bought a new position in Castle Biosciences during the fourth quarter worth $25,000. R Squared Ltd bought a new stake in Castle Biosciences in the 4th quarter valued at $42,000. KLP Kapitalforvaltning AS bought a new stake in Castle Biosciences in the 4th quarter valued at $128,000. China Universal Asset Management Co. Ltd. increased its holdings in Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after buying an additional 604 shares during the period. Finally, Oak Harvest Investment Services bought a new stake in Castle Biosciences in the 4th quarter valued at $206,000. Institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the transaction, the insider now owns 78,335 shares in the company, valued at $1,529,099.20. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 27,454 shares of company stock valued at $553,030 in the last quarter. 6.50% of the stock is currently owned by insiders.

Castle Biosciences Trading Up 1.3%

Castle Biosciences stock traded up $0.21 during trading hours on Friday, reaching $16.10. 287,423 shares of the company's stock traded hands, compared to its average volume of 405,787. Castle Biosciences, Inc. has a fifty-two week low of $15.66 and a fifty-two week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The firm has a market capitalization of $464.84 million, a price-to-earnings ratio of 80.50 and a beta of 1.19. The firm's 50 day moving average is $19.14 and its 200-day moving average is $24.53.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.12). The company had revenue of $87.99 million during the quarter, compared to analyst estimates of $80.40 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. On average, analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CSTL has been the topic of several analyst reports. Lake Street Capital lowered their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Scotiabank lowered their target price on shares of Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating on the stock in a report on Wednesday. Canaccord Genuity Group reduced their price target on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a "buy" rating in a research report on Friday, March 28th. Finally, Robert W. Baird upped their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $37.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.